Evidence map›Paper›PMID 33610093›Full record

ArticleDrug and alcohol dependence2021

Self-efficacy as a mediator of patient navigation interventions to engage persons living with HIV and substance use.

Sharleen M Traynor, Lisa R Metsch, Lauren Gooden, Maxine Stitzer, Tim Matheson, Susan Tross, Adam W Carrico, Mamta K Jain, Carlos Del Rio, Daniel J Feaster

Open access · greenAbstract read
In one paragraph

Article in Drug and alcohol dependence, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.1field-weighted citation impact, top 61% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 4 citations in OpenAlex.

  1. Trial
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 6 institutions in 1 country.

Sharleen M TraynorUniversity of Miami Miller School of Public Health, Department of Public Health Sciences, 1120 NW 14th Street, Miami, FL, 33136, USA. Electronic address: smtraynor@med.miami.edu.
Lisa R MetschColumbia University, Mailman School of Public Health, Department of Sociomedical Sciences, 2971 Broadway, 612 Lewisohn Hall, New York, NY, 10027, USA.
Lauren GoodenColumbia University, Mailman School of Public Health, Department of Sociomedical Sciences, 2971 Broadway, 612 Lewisohn Hall, New York, NY, 10027, USA.
Maxine StitzerJohns Hopkins University School of Medicine, Department of Psychiatry and Behavioral Sciences, 5510 Nathan Shock Drive, Suite 1500, Baltimore, MD, 21224, USA.
Tim MathesonSan Francisco Department of Public Health, Center for Public Health Research, 25 Van Ness Avenue, Suite 500, San Francisco, CA, 94102, USA.
Susan TrossColumbia University, Department of Psychiatry, 1051 Riverside Drive, New York, NY, 10032, USA.
Adam W CarricoUniversity of Miami Miller School of Public Health, Department of Public Health Sciences, 1120 NW 14th Street, Miami, FL, 33136, USA.
Mamta K JainUniversity of Texas Southwestern Medical Center, Department of Internal Medicine, 5323 Harry Hines Boulevard, Dallas, TX, 75390, USA.
Carlos Del RioEmory University School of Medicine, Division of Infectious Diseases, 100 Woodruff Circle, Atlanta, GA, 30322, USA.
Daniel J FeasterUniversity of Miami Miller School of Public Health, Department of Public Health Sciences, 1120 NW 14th Street, Miami, FL, 33136, USA.
Columbia University · USUniversity of Miami · USEmory University · USJohns Hopkins University · USSan Francisco Department of Public Health · USThe University of Texas Southwestern Medical Center · US

Funding

FLORIDA NODE OF THE DRUG ABUSE CLINICAL TRIALS NETWORKU10DA013720 · NIDA · UNIVERSITY OF MIAMI SCHOOL OF MEDICINE · PI METSCH, LISA R, SZAPOCZNIK, JOSE · 2000 to 2015
$56.9M
The Florida Node Alliance of the National Drug Abuse Treatment Clinical Trials NetworkUG1DA013720 · NIDA · UNIVERSITY OF MIAMI SCHOOL OF MEDICINE · PI Daniel J Feaster, Viviana Elizabeth Horigian · 2015 to 2026
$50.6M
University of Miami Developmental Center for AIDS Research (D-CFAR)P30AI073961 · NIAID · UNIVERSITY OF MIAMI SCHOOL OF MEDICINE · PI Savita Pahwa · 2007 to 2026
$33.8M
Clinical Trials Network: Mid-Atlantic Integrated Care Research CollaborativeUG1DA013034 · NIDA · JOHNS HOPKINS UNIVERSITY · PI SCHWARTZ, ROBERT P, STITZER, MAXINE L · 2015 to 2019
$11.0M
University of Miami Developmental HIV/AIDS Mental Health Research Center (D-ARC)P30MH116867 · NIMH · UNIVERSITY OF MIAMI CORAL GABLES · PI SAFREN, STEVEN A · 2019 to 2023
$6.5M
Training Program on HIV and Substance Use in the Criminal Justice SystemT32DA037801 · NIDA · COLUMBIA UNIV NEW YORK MORNINGSIDE · PI Nabila El-Bassel, Lisa R Metsch · 2014 to 2026
$5.7M
NIAID NIH HHS P30 AI073961NIDA NIH HHS T32 DA037801NIDA NIH HHS U10 DA013720NIDA NIH HHS UG1 DA013034NIDA NIH HHS UG1 DA013720NIMH NIH HHS P30 MH116867
6 · The paper itself

Abstract

backgroundPeople living with HIV who report substance use (PLWH-SU) face many barriers to care, resulting in an increased risk for poor health outcomes and the potential for ongoing disease transmission. This study evaluates the mechanisms by which Patient Navigation (PN) and Contingency Management (CM) interventions may work to address barriers to care and improve HIV outcomes in this population.

methodsMediation analysis was conducted using data from a randomized, multi-site trial testing PN interventions to improve HIV care outcomes among 801 hospitalized PLHW-SU. Direct and indirect effects of PN and PN + CM were evaluated through five potential mediators-psychosocial conditions, healthcare avoidance, financial hardship, system barriers, and self-efficacy for HIV treatment adherence-on engagement in HIV care and viral suppression.

resultsThe PN + CM intervention had an indirect effect on improving engagement in HIV care at 6 months by increasing self-efficacy for HIV treatment adherence (β = 0.042, 95% CI = 0.008, 0.086). PN + CM also led to increases in viral suppression at 6 months (β = 0.090, 95% CI = 0.023, 0.168) and 12 months (β = 0.069, 95% CI = 0.009, 0.129) via increases in self-efficacy, although the direct effects were not significant. No mediating effects were observed for PN alone.

conclusionPN + CM interventions for PLWH-SU can increase an individual's self-efficacy for HIV treatment adherence, which in turn improves engagement in care at 6 months and may contribute to viral suppression over 12 months. Building self-efficacy may be a key factor in the success of such interventions and should be considered as a primary goal of PN + CM in practice.

Indexed as

Self EfficacyAdultBehavior TherapyDelivery of Health CareFemaleHIV InfectionsHumansMaleMiddle AgedMotivationPatient NavigationSubstance-Related DisordersContingency managementHIV/AIDSMediation analysisPatient navigationSelf-EfficacySubstance use

Identifiers

PMID33610093
PMCPMC8067954
OpenAlexW3127745451

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.